Becton Dickinson and Co (NYSE:BDX) – Equities researchers at Jefferies Group raised their FY2018 earnings estimates for shares of Becton Dickinson and in a report issued on Tuesday. Jefferies Group analyst B. Couillard now forecasts that the medical instruments supplier will post earnings per share of $10.95 for the year, up from their previous forecast of $10.90. Jefferies Group also issued estimates for Becton Dickinson and’s Q4 2018 earnings at $3.04 EPS, Q2 2019 earnings at $3.09 EPS and FY2019 earnings at $12.70 EPS.
A number of other research analysts have also recently issued reports on BDX. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Wells Fargo & Co reiterated a “positive” rating and issued a $235.00 target price (up previously from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a “hold” rating and issued a $210.00 target price on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley lifted their target price on Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 target price on shares of Becton Dickinson and in a research report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Becton Dickinson and presently has an average rating of “Buy” and an average target price of $237.27.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 19.84% and a net margin of 2.71%. The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter last year, the business earned $2.33 earnings per share. Becton Dickinson and’s revenue was up 5.4% on a year-over-year basis.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.38%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.
Several large investors have recently added to or reduced their stakes in BDX. Legacy Advisors LLC grew its holdings in shares of Becton Dickinson and by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the last quarter. FTB Advisors Inc. grew its holdings in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the last quarter. Harfst & Associates Inc. grew its holdings in shares of Becton Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the last quarter. Penserra Capital Management LLC bought a new stake in shares of Becton Dickinson and during the fourth quarter worth about $136,000. Finally, Harvest Fund Management Co. Ltd grew its holdings in shares of Becton Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/08/becton-dickinson-and-co-bdx-to-post-fy2018-earnings-of-10-95-per-share-jefferies-group-forecasts.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.